Moderna (NASDAQ:MRNA) Price Target Lowered to $99.00 at The Goldman Sachs Group

Moderna (NASDAQ:MRNA) had its price objective decreased by analysts at The Goldman Sachs Group from $112.00 to $99.00 in a research report issued on Tuesday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. The Goldman Sachs Group’s price target suggests a potential upside of 126.43% from the company’s previous close.

MRNA has been the subject of a number of other research reports. Jefferies Financial Group decreased their price target on Moderna from $65.00 to $55.00 and set a “hold” rating for the company in a report on Tuesday, October 15th. JPMorgan Chase & Co. lowered their price target on shares of Moderna from $59.00 to $45.00 and set an “underweight” rating for the company in a report on Tuesday, November 26th. Evercore ISI cut their price objective on shares of Moderna from $60.00 to $50.00 and set an “in-line” rating on the stock in a report on Monday. HSBC raised shares of Moderna from a “hold” rating to a “buy” rating and set a $58.00 price objective for the company in a research report on Monday, November 18th. Finally, Wolfe Research initiated coverage on Moderna in a research note on Friday, November 15th. They issued an “underperform” rating and a $40.00 price target on the stock. Four equities research analysts have rated the stock with a sell rating, thirteen have issued a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Moderna currently has an average rating of “Hold” and a consensus price target of $69.79.

Moderna Trading Up 5.0 %

Shares of MRNA stock traded up $2.07 during mid-day trading on Tuesday, reaching $43.72. The company’s stock had a trading volume of 2,924,905 shares, compared to its average volume of 12,149,950. The company has a quick ratio of 4.20, a current ratio of 4.39 and a debt-to-equity ratio of 0.05. The firm has a market capitalization of $16.83 billion, a PE ratio of -7.55 and a beta of 1.60. The company’s 50 day simple moving average is $40.60 and its 200-day simple moving average is $63.29. Moderna has a 12-month low of $31.94 and a 12-month high of $170.47.

Moderna (NASDAQ:MRNA) last released its quarterly earnings data on Thursday, November 7th. The company reported $0.03 EPS for the quarter, beating the consensus estimate of ($1.89) by $1.92. Moderna had a negative return on equity of 17.68% and a negative net margin of 43.77%. The company had revenue of $1.90 billion for the quarter, compared to analyst estimates of $1.25 billion. During the same period last year, the company posted ($1.39) earnings per share. The firm’s revenue was up 3.8% compared to the same quarter last year. On average, research analysts predict that Moderna will post -9.27 EPS for the current fiscal year.

Insider Buying and Selling at Moderna

In related news, insider Shannon Thyme Klinger sold 1,418 shares of the stock in a transaction dated Friday, November 29th. The shares were sold at an average price of $42.79, for a total value of $60,676.22. Following the sale, the insider now owns 19,717 shares of the company’s stock, valued at $843,690.43. This trade represents a 6.71 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders sold a total of 2,664 shares of company stock worth $115,210 over the last ninety days. Company insiders own 15.70% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. State Street Corp lifted its holdings in Moderna by 12.1% in the third quarter. State Street Corp now owns 16,847,212 shares of the company’s stock worth $1,125,899,000 after purchasing an additional 1,823,276 shares during the period. Wellington Management Group LLP raised its position in shares of Moderna by 21.0% during the 3rd quarter. Wellington Management Group LLP now owns 5,224,685 shares of the company’s stock worth $349,166,000 after buying an additional 906,114 shares in the last quarter. Two Sigma Advisers LP acquired a new stake in shares of Moderna in the 3rd quarter worth approximately $23,825,000. International Assets Investment Management LLC boosted its holdings in shares of Moderna by 10,687.1% in the third quarter. International Assets Investment Management LLC now owns 319,514 shares of the company’s stock valued at $21,353,000 after acquiring an additional 316,552 shares in the last quarter. Finally, Douglas Lane & Associates LLC increased its stake in shares of Moderna by 62.9% during the fourth quarter. Douglas Lane & Associates LLC now owns 773,804 shares of the company’s stock valued at $32,175,000 after acquiring an additional 298,715 shares during the period. 75.33% of the stock is owned by institutional investors and hedge funds.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.